409 related articles for article (PubMed ID: 7691238)
1. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
[TBL] [Abstract][Full Text] [Related]
2. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
[TBL] [Abstract][Full Text] [Related]
3. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells.
Reusch U; Le Gall F; Hensel M; Moldenhauer G; Ho AD; Little M; Kipriyanov SM
Int J Cancer; 2004 Nov; 112(3):509-18. PubMed ID: 15382079
[TBL] [Abstract][Full Text] [Related]
4. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
[TBL] [Abstract][Full Text] [Related]
5. G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells.
Anderson PM; Crist W; Hasz D; Carroll AJ; Myers DE; Uckun FM
Blood; 1992 Dec; 80(11):2826-34. PubMed ID: 1280479
[TBL] [Abstract][Full Text] [Related]
6. Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma.
Haagen IA; Geerars AJ; de Lau WB; Clark MR; van de Griend RJ; Bast BJ; de Gast BC
Blood; 1994 Jul; 84(2):556-63. PubMed ID: 7517719
[TBL] [Abstract][Full Text] [Related]
7. CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow.
Manzke O; Berthold F; Huebel K; Tesch H; Diehl V; Bohlen H
Int J Cancer; 1999 Mar; 80(5):715-22. PubMed ID: 10048973
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibody fragments with CD20 X CD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma.
Brandl M; Grosse-Hovest L; Holler E; Kolb HJ; Jung G
Exp Hematol; 1999 Aug; 27(8):1264-70. PubMed ID: 10428503
[TBL] [Abstract][Full Text] [Related]
9. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Löffler A; Gruen M; Wuchter C; Schriever F; Kufer P; Dreier T; Hanakam F; Baeuerle PA; Bommert K; Karawajew L; Dörken B; Bargou RC
Leukemia; 2003 May; 17(5):900-9. PubMed ID: 12750704
[TBL] [Abstract][Full Text] [Related]
10. In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia.
Bonyhadi M; Frohlich M; Rasmussen A; Ferrand C; Grosmaire L; Robinet E; Leis J; Maziarz RT; Tiberghien P; Berenson RJ
J Immunol; 2005 Feb; 174(4):2366-75. PubMed ID: 15699173
[TBL] [Abstract][Full Text] [Related]
11. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).
Haagen IA; van de Griend R; Clark M; Geerars A; Bast B; de Gast B
Clin Exp Immunol; 1992 Dec; 90(3):368-75. PubMed ID: 1281055
[TBL] [Abstract][Full Text] [Related]
12. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
[TBL] [Abstract][Full Text] [Related]
13. Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
J Immunother; 1997 Sep; 20(5):325-33. PubMed ID: 9336739
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2.
Haagen IA; Geerars AJ; de Lau WB; Bast BJ; de Gast BC
Blood; 1995 Jun; 85(11):3208-12. PubMed ID: 7538821
[TBL] [Abstract][Full Text] [Related]
15. Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic.
Haagen IA; de Lau WB; Bast BJ; Geerars AJ; Clark MR; de Gast BC
Cancer Immunol Immunother; 1994 Dec; 39(6):391-6. PubMed ID: 7528094
[TBL] [Abstract][Full Text] [Related]
16. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
[TBL] [Abstract][Full Text] [Related]
17. Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity.
Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
Clin Exp Immunol; 1997 May; 108(2):352-7. PubMed ID: 9158110
[TBL] [Abstract][Full Text] [Related]
18. The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells.
Koulova L; Clark EA; Shu G; Dupont B
J Exp Med; 1991 Mar; 173(3):759-62. PubMed ID: 1847724
[TBL] [Abstract][Full Text] [Related]
19. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.
Klein SC; Boer LH; de Weger RA; de Gast GC; Bast EJ
Scand J Immunol; 1997 Nov; 46(5):452-8. PubMed ID: 9393627
[TBL] [Abstract][Full Text] [Related]
20. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2.
Gimmi CD; Freeman GJ; Gribben JG; Sugita K; Freedman AS; Morimoto C; Nadler LM
Proc Natl Acad Sci U S A; 1991 Aug; 88(15):6575-9. PubMed ID: 1650475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]